As SGLT2 inhibitors redefine standard of care, opportunities to establish efficacy with surrogate endpoints take a step forward, and molecular phenotyping of disease etiology enables reclassification of patients to clinically actionable subtypes; drug development for chronic kidney disease has never been more exciting.
The 4th Chronic Kidney Disease Drug Development Summit (previously CKD3) is your only industry-led event dedicated to accelerating the frontier of preventative and regenerative therapies to meaningfully target kidney disease and enlighten opportunities for indication expansion into rare renal disorders. Uniting 100+ industry heavyweights including AstraZeneca, Johnson & Johnson, Bayer, Boehringer Ingelheim, Novartis, Otsuka, Novo Nordisk, and many more, this is a conversation you cannot afford to miss.
From dissecting pivotal insight into implementing patient stratification to turn the tide on precision medicine, to the brand-new seminar dedicated to establishing a pathway to clinical success in AKI, this is the only end-to-end forum presenting scientific advancements as actionable insights.
We hope to see you in Boston this March to together discover opportunities to personalize organ-on-a-chip technology and explore advances in stem cell platforms to regenerate kidney tissue. Leave this meeting equipped to guide your strategic decisions for 2022 and implement evolving surrogate endpoints of eGFR slope, albuminuria, and real-world evidence into innovative trial design.
“The annual CKD3 Summit is a wonderful opportunity to connect with colleagues who are committed to making a difference for people with kidney diseases and hear about important scientific progress in the field."
"CKD3 offers an in depth look at the groundbreaking innovation in omics advancing our knowledge of kidney diseases and their potential treatment.”
"The CKD Summit provides up to date information on the research of the biggest names in the CKD clinical development field and the opportunity to ask presenters questions about their work and the rationale behind it, which will go beyond reading their journal articles."
"A forum of experts opened to new ideas.”